Sustained API price weakness
API prices have declined 10-12% over the last 12 months and continue to slide, impacting CDMO revenue growth and margins.
AKUMS / Q1-FY26 / risks
Keep the risk register visible.
Akums Drugs and Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Slow ramp-up in European exports
European dossier approvals and commercial supplies are still in early stages; achieving $100 million export target in 5 years may be delayed if regulatory or market access hurdles arise.
Trade generic and API losses persist
Trade generic segment posted negative EBITDA of ₹5 crore, and API business reported a loss of ₹6 crore. Management is rationalizing but turnaround timeline is uncertain.
GLP-1 opportunity not being pursued
Management confirmed they are not targeting semaglutide, citing limited CDMO addressable market as most players do it in-house. This could mean missing a large growth opportunity.